Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report. Monaldi Arch Chest Dis [Internet]. 2022 Nov. 25 [cited 2025 Jun. 13];93(4). Available from: https://www.monaldi-archives.org/macd/article/view/2440